Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Multiple Sclerosis | Unmet Need | Relapsing | US/FR/DE/UK | 2020

Login to access report north_east
Contact sales account_box

A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis , the most prevalent form of MS. Nevertheless, all approved drugs have clinical shortcomings in terms of efficacy, safety, tolerability, and/or delivery, creating opportunities for new and improved DMTs, be they incremental or pioneering. This content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the management of relapsing MS and the current level of unmet need in this area. We analyze the commercial opportunities and how new / emerging novel and next-generation compounds may capitalize on these opportunities.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for relapsing forms of MS?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals?
  • What are the prevailing areas of unmet need and opportunity in relapsing MS?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for relapsing MS?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
north_east
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used in parallel to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via…
north_east
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
north_east
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
north_east
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east